Not for inj or ingestion. Discontinue treatment if hypersensitivity develops. Cross-hypersensitivity to other aminoglycosides. Risk of neurotoxicity, ototoxicity & nephrotoxicity w/ systemic aminoglycoside therapy. Caution in patients w/ known or suspected neuromuscular disorders eg, myasthenia gravis or Parkinson's disease. Excessive &/or prolonged use may increase risk of ocular complications & systemic side effects; cause hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, & decreased growth rate in childn; ocular HTN &/or glaucoma, w/ damage to the optic nerve, reduced visual acuity & visual field defects, & posterior subcapsular cataract formation; reduce resistance to & aid in establishment of bacterial, viral, fungal, or parasitic infections & mask clinical signs of infection. Routinely & frequently check IOP in patients receiving ophth corticosteroid therapy for ≥10 days. Visual disturbance. Should only be used in acute purulent eye infections when treatment w/ steroid/anti-infective combination product is necessary. May result in overgrowth of non-susceptible organisms, including fungi. Use w/ caution when treating herpes simplex other than epithelial herpes simplex keratitis. Perforations may occur in diseases causing thinning of the cornea or sclera. Topical ophth corticosteroid may slow corneal wound healing. Concomitant use w/ topical NSAIDs & topical steroids. Do not discontinue treatment prematurely. Risk of corticosteroid-induced raised IOP &/or cataract formation in predisposed patients (eg, diabetes). Contact lens wear is not recommended. May affect the ability to drive & use machines. Not recommended during pregnancy. Lactation. Paed patients. Ophth susp:
Contains benzalkonium Cl.